SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): August 18, 2008
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-22705
|
|
33-0525145 |
| (State or other
|
|
(Commission File
|
|
(IRS Employer Identification |
| jurisdiction of
|
|
Number)
|
|
No.) |
| incorporation or |
|
|
|
|
| organization) |
|
|
|
|
| |
|
|
|
|
12780 El Camino Real
San
Diego, CA
|
|
|
|
92130 |
| (Address of principal executive
|
|
|
|
(Zip Code) |
| offices) |
|
|
|
|
Registrant’s telephone number, including area code: (858) 617-7600
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2 (b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4 (c))